KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Other Accumulated Expenses (2020 - 2025)

Oscar Health's Other Accumulated Expenses history spans 6 years, with the latest figure at $1.5 billion for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 7.27% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, up 7.27%, while the annual FY2025 figure was $1.5 billion, 7.27% up from the prior year.
  • Other Accumulated Expenses reached $1.5 billion in Q4 2025 per OSCR's latest filing, down from $1.6 billion in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.6 billion in Q3 2025 to a low of $358.1 million in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $1.0 billion, with a median of $960.0 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 116.17% in 2022, then fell 8.57% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $513.6 million in 2021, then skyrocketed by 82.59% to $937.7 million in 2022, then increased by 3.01% to $966.0 million in 2023, then soared by 40.45% to $1.4 billion in 2024, then rose by 7.27% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for OSCR's Other Accumulated Expenses are $1.5 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.6 billion (Q2 2025).